Implantation of a Tissue-engineered Heart Valve from Human Fibroblasts Exhibiting Short Term Function in the Sheep Pulmonary Artery


We have previously demonstrated the feasibility of fabricating a fibrin-based tissue-engineered heart valve (TEHV) using neonatal human dermal fibroblasts (nhDF), including leaflets with structural and mechanical anisotropy similar to native leaflets. The aim here was to evaluate the performance of this TEHV in a pilot study using the sheep model. Bi-leaflet TEHV were conditioned in a cyclic stretching bioreactor, then implanted within a polymeric sleeve interpositionally into the pulmonary artery of four sheep, with the pulmonary valve either left intact or rendered incompetent. Heparin and immunosuppression were administered for the duration. Echocardiography was performed at implantation and at 4 and 8 weeks. Explants were examined histologically, biochemically, and mechanically. In all sheep, echocardiography at implantation showed coapting leaflets, with minimal valve regurgitation and no turbulence. Orifice area and pressure gradients at systole approached the native pulmonary valve values. Echocardiography at 4 weeks revealed both leaflets functional with moderate regurgitation and turbulence in three sheep; in one sheep, only one leaflet was evident. Explanted leaflets had thickness and tensile properties comparable to the implanted leaflets. There was extensive endothelialization of the root lumenal surface. In the two sheep continued to 8 weeks, only one shortened leaflet remained in both cases. Immunocytochemistry indicated this was due to sustained tissue contraction caused by the nhDF and not by the invading host cells, which included a subpopulation consistent with bone marrow-derived cells. Short-term success was thus achieved in terms of excellent valve function at implantation and some valve function for at least 4 weeks; however, an apparent progressive tissue contraction needs to be resolved for long-term success.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6


  1. 1.

    Allen, H. D., D. J. Driscoll, R. E. Shaddy, and T. F. Feltes. Moss and Adams’ Heart Disease in Infants, Children, and Adolescents. Philadelphia: Lippincott Williams & Wilkins, 2008.

  2. 2.

    Flanagan, T. C., J. S. Sachweh, J. Frese, H. Schnoring, N. Gronloh, S. Koch, et al. In vivo remodeling and structural characterization of fibrin-based tissue-engineered heart valves in the adult sheep model. Tissue Eng. 15:2965–2976, 2009.

  3. 3.

    Gallegos, R. P., P. J. Nockel, A. L. Rivard, and R. W. Bianco. The current state of in vivo pre-clinical animal models for heart valve evaluation. J. Heart Valve Dis. 14:423–432, 2005.

  4. 4.

    Gong, X. J., X. Q. Zhang, Y. Song, Y. H. Li, X. Y. Pang, and S. X. Li. Effects of immunosuppressive treatment in prevention of calcification in aortic valved homograft: experiment with rats. Zhonghua yi xue za zhi 87:2132–2135, 2007.

  5. 5.

    Gottlieb, D., T. Kunal, S. Emani, E. Aikawa, D. W. Brown, A. J. Powell, et al. In vivo monitoring of function of autologous engineered pulmonary valve. J. Thorac. Cardiovas. Surg. 139:723–731, 2010.

  6. 6.

    Grassl, E. D., T. R. Oegema, and R. T. Tranquillo. Fibrin as an alternative biopolymer to type I collagen for fabrication of a media-equivalent. J. Biomed. Mater. Res. 60:607–612, 2002.

  7. 7.

    Grinnell, F., and C. H. Ho. Transforming growth factor beta stimulates fibroblast-collagen matrix contraction by different mechanisms in mechanically loaded and unloaded matrices. Exp. Cell Res. 273:248–255, 2002.

  8. 8.

    Hoerstrup, S. P., R. Sodian, S. Daebritz, J. Wang, E. A. Bacha, D. P. Martin, et al. Functional living trileaflet heart valves grown in vitro. Circulation 102:III44–III49, 2000.

  9. 9.

    Jockenhoevel, S., K. Chalabi, J. S. Sachweh, H. V. Groesdonk, L. Demircan, M. Grossmann, et al. Tissue engineering: complete autologous valve conduit—a new moulding technique. Thorac. Cardiovasc. Surg. 49:287–290, 2001.

  10. 10.

    Kim, B. S., and D. J. Mooney. Engineering smooth muscle tissue with a predefined structure. J. Biomed. Mater. Res. 41:322–332, 1998.

  11. 11.

    L’Heureux, N., N. Dusserre, G. Konig, B. Victor, P. Keire, T. N. Wight, et al. Human tissue-engineered blood vessels for adult arterial revascularization. Nat. Med. 12:361–365, 2006.

  12. 12.

    L’Heureux, N., T. N. McAllister, and L. M. de la Fuente. Tissue-engineered blood vessel for adult arterial revascularization. N. Engl. J. Med. 357:1451–1453, 2007.

  13. 13.

    Long, J. L., and R. T. Tranquillo. Elastic fiber production in cardiovascular tissue-equivalents. Matrix Biol. 22:339–350, 2003.

  14. 14.

    McAllister, T. N., M. Maruszewski, S. A. Garrido, W. Wystrychowski, N. Dusserre, A. Marini, et al. Effectiveness of haemodialysis access with an autologous tissue-engineered vascular graft: a multicentre cohort study. Lancet 373:1440–1446, 2009.

  15. 15.

    Mol, A., M. C. Rutten, N. J. Driessen, C. V. Bouten, G. Zund, F. P. Baaijens, et al. Autologous human tissue-engineered heart valves: prospects for systemic application. Circulation 114:I152–I158, 2006.

  16. 16.

    Mrugala, D., C. Bony, N. Neves, L. Caillot, S. Fabre, D. Moukoko, et al. Phenotypic and functional characterisation of ovine mesenchymal stem cells: application to a cartilage defect model. Ann. Rheum. Dis. 67:288–295, 2008.

  17. 17.

    Robinson, P. S., and R. T. Tranquillo. Planar biaxial behavior of fibrin-based tissue-engineered heart valve leaflets. Tissue Eng. 15:2763–2772, 2009.

  18. 18.

    Robinson, P. S., S. L. Johnson, M. C. Evans, V. H. Barocas, and R. T. Tranquillo. Functional tissue-engineered valves from cell-remodeled fibrin with commissural alignment of cell-produced collagen. Tissue Eng. Part A 14:83–95, 2008.

  19. 19.

    Rosamond, W., K. Flegal, K. Furie, A. Go, K. Greenlund, N. Haase, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117:e25–e146, 2008.

  20. 20.

    Sabet, H. Y., W. D. Edwards, H. D. Tazelaar, and R. C. Daly. Congenitally bicuspid aortic valves: a surgical pathology study of 542 cases (1991 through 1996) and a literature review of 2,715 additional cases. Mayo Clin. Proc. 74:14–26, 1999.

  21. 21.

    Schmidt, D., P. E. Dijkman, A. Driessen-Mol, R. Stenger, C. Mariani, A. Puolakka, et al. Minimally-invasive implantation of living tissue engineered heart valves: a comprehensive approach from autologous vascular cells to stem cells. J. Am. Coll. Cardiol. 56:510–520, 2010.

  22. 22.

    Sodian, R., S. P. Hoerstrup, J. S. Sperling, S. Daebritz, D. P. Martin, A. M. Moran, et al. Early in vivo experience with tissue-engineered trileaflet heart valves. Circulation 102:III22–III29, 2000.

  23. 23.

    Sodian, R., S. P. Hoerstrup, J. S. Sperling, S. H. Daebritz, D. P. Martin, F. J. Schoen, et al. Tissue engineering of heart valves: in vitro experiences. Ann. Thorac. Surg. 70:140–144, 2000.

  24. 24.

    Stegemann, H., and K. Stalder. Determination of hydroxyproline. Clin. Chim. Acta Int. J. Clin. Chem. 18:267–273, 1967.

  25. 25.

    Sung, H. J., C. Meredith, C. Johnson, and Z. S. Galis. The effect of scaffold degradation rate on three-dimensional cell growth and angiogenesis. Biomaterials 25:5735–5742, 2004.

  26. 26.

    Sutherland, F. W., T. E. Perry, Y. Yu, M. C. Sherwood, E. Rabkin, Y. Masuda, et al. From stem cells to viable autologous semilunar heart valve. Circulation 111:2783–2791, 2005.

  27. 27.

    Syedain, Z. H., and R. T. Tranquillo. Controlled cyclic stretch bioreactor for tissue-engineered heart valves. Biomaterials 30:4078–4084, 2009.

  28. 28.

    Syedain, Z. H., J. S. Weinberg, and R. T. Tranquillo. Cyclic distension of fibrin-based tissue constructs: evidence of adaptation during growth of engineered connective tissue. Proc. Natl Acad. Sci. U.S.A. 105:6537–6542, 2008.

Download references


The authors acknowledge Naomi Ferguson, Cary Valley, Stephen Stephens, Ricky Chow, and Linisia Wahyudi for technical assistance. Funding was provided by the National Institutes of Health (USA) BRP HL71538 to R.T.T.

Conflict of interest

The authors have no conflicts of interest with the reported study to disclose.

Author information

Correspondence to Robert T. Tranquillo.

Additional information

Associate Editor Jane Grande-Allen oversaw the review of this article.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (AVI 5282 kb)

Supplementary material 2 (AVI 9170 kb)

Supplementary material 3 (AVI 4253 kb)

Supplementary material 4 (AVI 1835 kb)

Supplementary material 1 (AVI 5282 kb)

Supplementary material 2 (AVI 9170 kb)

Supplementary material 3 (AVI 4253 kb)

Supplementary material 4 (AVI 1835 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Syedain, Z.H., Lahti, M.T., Johnson, S.L. et al. Implantation of a Tissue-engineered Heart Valve from Human Fibroblasts Exhibiting Short Term Function in the Sheep Pulmonary Artery. Cardiovasc Eng Tech 2, 101–112 (2011) doi:10.1007/s13239-011-0039-5

Download citation


  • Tissue-engineering
  • Heart valve
  • Fibrin
  • Fibroblast
  • Ovine